Dare Bioscience

DARE

Market cap $27.4M

Engagement Will Expand Daré's Engagement in Advancing Women's Health Innovation and Provide Insights into One of the Most Significant Unmet Needs in Maternal Care Engagement Will Expand Daré's Engagement in Advancing Women's Health Innovation and Provide Insights into One of the Most Significant Unmet Needs in Maternal Care

Daré Bioscience, Inc. (NASDAQ:DARE ) Q2 2025 Earnings Conference Call August 14, 2025 4:30 PM ET Company Participants MarDee J. Haring-Layton - Chief Accounting Officer Sabrina Martucci Johnson - CEO, President, Principal Financial Officer, Secretary & Director Operator Welcome to the conference call hosted by Daré Bioscience Therapeutics Company's Second Quarter 2025 Financial Results and to provide a business update.

Dare Bioscience, Inc. (DARE) came out with a quarterly loss of $0.45 per share versus the Zacks Consensus Estimate of a loss of $0.55. This compares to earnings of $1.52 per share a year ago.

DARE to PLAY™ Sildenafil Cream on Track for Q4 2025 Launch via 503B Compounding Pathway; Positioned for Product Revenue Beginning in Q4 2025

SAN DIEGO, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a biopharmaceutical company with a sole focus of closing the gap in women's health between promising science and real solutions, will host a conference call and live webcast at 4:30 p.m. Eastern Time on Thursday, August 14, 2025, to review its financial results for the quarter ended June 30, 2025 and to provide a company update.

A first-of-its-kind solution for women's arousal in a proprietary topical formulation demonstrated to work where women need it most

A first-of-its-kind solution for women's arousal - the same active ingredient as in Viagra® for men - in a proprietary topical formulation demonstrated to work where women need it most

U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining around 0.4% on Monday.

Interim Phase 3 Results Support Ovaprene's Differentiation as a First-in-Category, Hormone-Free, Intravaginal Monthly Contraceptive Interim Phase 3 Results Support Ovaprene's Differentiation as a First-in-Category, Hormone-Free, Intravaginal Monthly Contraceptive

Exploring Strategic Partnerships to Expand Platform Beyond Reproductive Health Exploring Strategic Partnerships to Expand Platform Beyond Reproductive Health